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Contributions
N. Meltem Daysal* and Chiara Orsini
Spillover Effects of Drug Safety Warnings on
Preventive Health Care Use
Abstract: We examine how new medical information on drug safety impacts
preventive health care use. We exploit the release of the findings of the Women’s
Health Initiative Study (WHIS) – the largest randomized controlled trial of
women’s health – which demonstrated in 2002 the health risks associated with
the long-term use of hormone replacement therapy (HRT). We first show that,
after the release of the WHIS findings, HRT use dropped sharply among post-
menopausal women. We then estimate the spillover effects of the WHIS findings
on preventive care by means of a difference-in-differences methodology compar-
ing changes in preventive care use among 60 to 69 year-old women (who have
high rates of HRT use) with the change among women aged 75 and above (who
have much lower rates of HRT use). Using data from the Behavioral Risk Factor
Surveillance System for the period 1998–2007, we find that women aged 60–69
had statistically and economically significant declines in their annual mammo-
graphy checks, checkups, cholesterol checks and blood stool tests, when com-
pared to older women.
Keywords: spillovers, preventive behavior, health production
DOI 10.1515/bejeap-2013-0038
1 Introduction
In the United States, consumers obtain medical information from a variety
of sources, including results of new medical research, direct-to-consumer
advertisements (DTCA), Food and Drug Administration (FDA) warnings and
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announcements and medical report cards. The production and dissemination of
new medical information has substantial costs. National spending on research
and development almost doubled during the past decade, from $25.5 billions in
2000 to $48.1 billions in 2012.1 Annual spending on DTCA reached $4,237
millions in 2005 (Donohue, Cevasco, and Rosenthal 2007). Similarly, significant
sums of public resources are devoted to the preparation and distribution of
medical report cards and FDA announcements and warnings. Consequently,
the question of how new medical information impacts consumers has long
been of interest to both researchers and policy-makers.
While an extensive body of research shows that individuals change their
consumption patterns in response to new drug-related information, the parallel
question of how new medical information on drugs impacts a healthy lifestyle
and preventive health behavior is largely unexplored. In this paper, we investi-
gate how findings of new medical research and the subsequent policy warnings
on the safety of preventive drugs impact preventive health care use. In particu-
lar, we examine the response to the findings of the Women’s Health Initiative
Study (WHIS) which demonstrated in 2002 that long-term Hormone Replacement
Therapy (HRT) increases the risk of heart attacks, stroke, blood clots and breast
cancer among healthy post-menopausal women.2
We focus on the information provided by the WHIS for a number of
reasons. First, there are no real substitutes for the preventive care provided
by HRT. The main reason for HRT use among post-menopausal women was to
prevent post-menopausal osteoporosis and heart disease, with the latter gain-
ing more emphasis during the 1990s.3 The published guidelines for the pri-
mary prevention of cardiovascular disease indicate that HRT has been the only
pharmacological intervention recommended to reduce the risk of cardiovas-
cular disease.
1 These figures exclude research and development expenditures by drug companies and other
manufacturers. Taken from the National Health Expenditure Accounts available at https://www.
cms.gov/NationalHealthExpendData/downloads/tables.pdf, accessed on March 30, 2014.
2 HRT is a treatment for women that involves taking small doses of female hormones lost due
to the aging process. We discuss the history of and the indications for HRT in more detail in
Section 2.2. Several other studies have exploited the findings of new medical research in other
contexts (see, for example, Price and Simon 2009). Similarly, FDA black box warnings have
been exploited in various other contexts (e.g. Parkinson et al. 2008; Soumerai et al. 1987;
Weatherby et al. 2002; Wagner et al. 2006). Given the pace of medical research and the
frequency with which FDA requires black box warnings, our results are relevant to similar
future events.
3 HRT is also used by middle-aged women as a short-term treatment to alleviate negative
symptoms of menopause.
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Second, the WHIS is an ideal source of exogenous variation in drug safety
information as it is the largest randomized controlled trial of women’s health
ever undertaken.4 The HRT component, the most debated and closely followed
part of the study, was initially scheduled to run until 2005 but was abruptly
terminated on July 9, 2002 due to increased health risks among the treated. The
story made major headlines across the country. Soon after, in January 2003, the
FDA announced a formal name change for HRT drugs as “menopausal hormone
therapy”, emphasizing its short-term indication in relieving menopausal symp-
toms, and mandated a boxed warning on the label of HRT drugs informing
consumers about the increased risks associated with post-menopausal HRT use.
The WHIS results had a remarkable effect on the use and prescription of HRT
drugs among post-menopausal women. Figure 1(a) shows the share of women aged
60–69 and 75 and olderwho reportedhaving purchased at least oneHRT product for
the period 1998–2007.5 While HRT use is significantly lower among older ages, the
figure shows that HRT use declined by roughly 50% among both age groups:
fraction of 60–69 (75þ ) year-oldwomen using HRT declined from 31% (12%) during
the WHIS period to 14% (6%) during the post-WHIS period. Similarly, Figure 1(b)
shows that the share of office-visits amongpost-menopausalwomen that resulted in
an HRT prescription declined by 50% from the pre-announcement period of the
WHIS results (1998–2002) to the period thereafter (2003–2007).
We examine the effects of the WHIS findings on the preventive health care
use of post-menopausal women by means of a difference-in-differences metho-
dology. Given the difficulty in finding an appropriate control group to describe
the counterfactual of how post-menopausal women would have behaved in the
absence of the WHIS intervention, we identify the effects by comparing changes
in outcomes among more intensively treated 60–69 year-old women with
the change among less intensively treated 75þ year-old women.6 Using data
from the Behavioral Risk Factor Surveillance System (BRFSS) for the period
1998–2007, we find statistically and economically significant reductions in the
preventive health care use of women aged 60–69 relative to women aged 75 and
above. In particular, our results suggest that women aged 60–69 group had a
decline of 4.8% in annual mammography checks, 2.14% in annual checkups,
3.54% in annual cholesterol checks and 8.37% in annual blood stool tests, when
compared to older post-menopausal women. These results are robust to a host
of checks.
4 More information on the WHIS is provided in Section 2.3.
5 A detailed description of the data sources used to construct these graphs is provided in the
Appendix.
6 In Section 5.3, we show that our results are robust to using alternative comparison groups.
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Figure 1: Prevalence of HRT among post-menopausal women. (a) HRT use among women:
Medical Expenditure Panel Survey, 1998–2007; (b) HRT prescriptions among office visits:
National Ambulatory Medical Care Survey, 1998–2007
182 N. M. Daysal and C. Orsini
Brought to you by | EP Ipswich
Authenticated
Download Date | 10/16/15 11:51 AM
This paper’s empirical work is most related to the theory of risk com-
pensation. According to this theory, people adjust their behavior in response
to perceived changes in risk in such a way that keeps the risk level constant.
This offsetting behavior has been referred to as the “Peltzman Effect” or
“lulling effect” in previous studies. Empirical evidence on the presence of
offsetting behavior is mixed. For example, Kahn (1999) studies the effects of
the availability of new diabetic medications on diet and does not find any
evidence that access to improved medications led to worse health habits.
Peltzman (2002), on the other hand, investigates the impact of the develop-
ment of antibiotics on mortality and finds that the development increased
the mortality risk among age groups and in regions that were most likely to
benefit from the innovation. He interprets this as suggestive evidence of
offsetting behavior where individuals adopt risky health behaviors in
response to the availability of a curative product. These and other studies
(summarized in the next section) exclusively examined the unintended
effects of “positive” information on health behavior. Different from this
literature, we examine the effects of “negative” information, i.e. the harmful
effects of HRT. This is an important distinction as results may differ from the
predictions based on studies involving positive information if there are
asymmetric responses to positive and negative information. While existence
of asymmetric responses has received attention in other areas (e.g. over the
business cycle), this question has not been explored in this context before.
Our work is also related to theories on cognitive dissonance, hyperbolic
discounting, fatalism and the health belief model. We discuss these theories
in Section 5.4.
While data limitations constrain our ability to pinpoint the exact mechan-
isms leading to the observed spillover effects, we advance the literature in
several ways. As described in detail in Section 2.1, previous studies on
this topic exclusively focused on the effects of marketing and availability of
curative products on health behavior. In contrast, we study responses to the
findings of a highly publicized randomized trial and the subsequent FDA
warnings. Second, we examine how information on the safety of a preventive
drug impacts health behavior, which may differ from the impact of curative
products on health behavior. Third, the marketing and availability of curative
products involve the provision of positive information (i.e. that there is a
cure available). As noted above, our study investigates consequences of
providing “negative” information. Finally, to our knowledge, our study is
the first to use a quasi-experiment when investigating responses to new
medical information and thus improves upon previous studies that may suffer
from various endogeneity biases.
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Our results have important insights for drawing a more complete picture of
the value of new medical information. In particular, these findings suggest that
any cost–benefit analysis on the value of medical information should take these
behavioral spillovers into account.
The remainder of the paper is organized as follows. Section 2 presents a
background on the related literature, HRT and WHIS. Section 3 introduces the
data, while Section 4 outlines the empirical framework. The results are pre-
sented in Section 5 along with robustness checks and a discussion on potential
mechanisms. Finally, Section 6 concludes.
2 Background
2.1 Previous literature
Our work is related to the extensive body of research showing that consumers
are generally responsive to medical information. Drug sales are found to be
related to marketing information, FDA warnings and scientific evidence (Berndt
et al. 1995; Azoulay 2002; Parkinson et al. 2008) and exposure to advertising is
shown to increase the probability of quitting smoking (Avery et al. 2007) as well
as compliance with the advertised drug therapy (Calfee, Winston, and Stempski
2002). Similarly, previous literature documents that the quality information
provided by plan ratings and report cards has a significant impact on indivi-
duals’ choice of health plans and health care providers (Dranove et al. 2003;
Chernew, Gowrisankaran, and Scanlon 2004; Cutler, Huckman, and Landrum
2004; Dafny and Dranove 2008).
Past research also shows that the consumption effects of medical informa-
tion pertaining to specific drugs are not restricted to those drugs only, but that
there are spillovers to others. Evidence suggests that DTCA on prescription drugs
increases the sales of the same-brand over-the-counter medications (Ling,
Berndt, and Kyle 2002) and compliance with drug therapy for all medications
(Wosinska 2005), and that the FDA prescription drug withdrawals lead to
reduced utilization of the non-withdrawn drugs within the same therapeutic
class (Cawley and Rizzo 2008).
Despite its potentially important public policy implications, the related
question of how new medical information on drugs impacts a healthy lifestyle
has received very little attention. Iizuka and Jin (2005) and Iizuka and Jin
(forthcoming) use instrumental variable methods and find that DTCA exposure
is associated with increased doctor visits but reduced likelihood of engaging in
184 N. M. Daysal and C. Orsini
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moderate exercise.7 Conducting a series of experiments, Bolton, Cohen, and
Bloom (2006) and Bolton et al. (2008) find that marketing of curative drugs
related to various risky health behaviors, such as smoking and having a high-fat
diet, increases intentions to engage in risky behavior. Finally, as discussed in
the introduction, Kahn (1999) and Peltzman (2002) examine the impact of
medical breakthroughs on subsequent preventive health behavior. We add to
this small but growing literature by examining the impact of new medical
information on drug safety on preventive health care use.
2.2 Hormone replacement therapy
Hormone replacement therapy is a treatment that involves taking small doses of
female hormones that the natural aging process takes away. Female hormones
(estrogen and progesterone) are produced naturally by the ovaries. As women
approach menopause, i.e. their final menstrual period, their ovaries shrink and
the levels of female hormones start to fluctuate.8 During the years immediately
before menopause (peri-menopause) and the years that follow (post-meno-
pause), the production of female hormones gradually slows down and even-
tually stops. Peri-menopausal and menopausal women can experience negative
symptoms, such as hot flashes, night sweats, sleep disturbances and vaginal
atrophy, as their bodies try to adapt to reduced hormone levels. Although most
of these symptoms disappear during post-menopausal years, post-menopausal
women face increased risk for serious health problems, such as heart disease,
stroke, and bone loss that can result in osteoporosis and fractures.9
During the early twentieth century, HRT was mainly intended as a short-
term therapy to relieve the negative symptoms of menopause (Watkins 2007).
7 Iizuka and Jin (2005) estimate the impact of DTCA intensity on a given drug class in a given
month on the number of doctor visits related to that drug class, controlling for drug class and
month effects as well as class-specific time-trends and class-specific seasonality. Iizuka and Jin
(forthcoming) estimate linear probability models that relate the likelihood that a given indivi-
dual from a given MSA and year engages in moderate/vigorous exercise to the intensity of DTCA
in that MSA from four specific conditions (diabetes, hypertension, high cholesterol and over-
weight), observable characteristics, drug-class and year effects. In both cases, they use a given
drug companies’ DTCA expenditures in unrelated drug classes as an instrument for the measure
of DTCA. However, this instrument violates exclusion restrictions if there are common factors
that determine how companies target prescription drug advertising.
8 A woman is classified to be in menopause if she did not have any menstrual periods for 12
consecutive months without being ill, pregnant or breast-feeding.
9 For more information on the menopause transition, see The North American Menopause
Society (2006), National Heart, Lung and Blood Institute (2005).
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The idea that HRT could be used as a long-term therapy to improve the health of
post-menopausal women emerged during the mid-twentieth century as scientists
put forward the hypothesis linking reduced female hormones to the onset of
osteoporosis, cardiovascular disease and dementia, and drew analogies between
estrogen deficiency after menopause and insulin deficiency in diabetes (Watkins
2007). Watkins (2007) notes that the April 1984 osteoporosis treatment consen-
sus group of the National Institutes of Health recommended estrogen therapy
without specific limitations to its duration of use. Soon after that, the Food and
Drug Administration added in April 1986 the treatment of post-menopausal
osteoporosis to the indications of HRT10 and recommended in a special two-
day workshop that any woman over the age of 50 should be seen as a candidate
for long-term HRT (Watkins 2007). The American College of Physicians agreed
with these recommendations stating in their 1992 guidelines for counseling post-
menopausal women that “all women, regardless of race, should consider pre-
ventive hormone therapy” (American College of Physicians 1992, p. 1038).
The available statistics from these periods reflect the increased popularity of
HRT as a long-term preventive medication. The number of oral estrogen pre-
scriptions increased from 13.6 millions in 1982 to 20.1 millions in 1987 to 36.5
millions in 1992 (Wysowski, Golden, and Burke 1995). Furthermore, the share of
oral estrogens prescribed to post-menopausal women aged 60 and above
increased from 19% in 1979 to 25% in 1986 to 30% in 1992 (Hemminki et al.
1988; Wysowski et al. 1995).11 Premarin, the conjugated estrogen by Wyeth-
Ayerst Laboratories, became the most frequently prescribed drug in 1992 and
remained in the top two most prescribed drugs in the United States for every
year during the 1990s (Watkins 2007).
Given the widespread HRT use and the aging of the American population,
the 1990s began with an even more pronounced need for a reliable study
examining the effects of long-term HRT on the health of post-menopausal
women. It is then not surprising that out of this need the National Institutes of
Health established in September 1990 the Office of Research on Women’s
Health, which would soon found the Women’s Health Initiative Study.
2.3 Women’s Health Initiative Study
The Women’s Health Initiative Study was launched in April 1991 with the aim of
evaluating the effectiveness of several strategies for preventing major diseases
10 Food and Drug Administration (1986).
11 The statistic for 1992 reflects the share of Premarin prescriptions dispensed to women aged 60
and above. Premarin was the most commonly used oral estrogen in 1992 (Wysowski et al. 1995).
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and promoting good health among post-menopausal women.12 The study, spon-
sored by the National Heart, Lung, and Blood Institute, consisted of three
components: a clinical trial, an observational study and a community prevention
study. The clinical trial further had a Hormone Therapy component aimed to
examine the preventive effects of HRT on heart disease and osteoporosis, keep-
ing in mind the potential risks for breast cancer.
Between October 1993 and October 1998, the study recruited more than
160,000 participants, of which more than 68,000 were assigned to the clinical
trials and nearly 28,000 women were assigned to the HRT trials. Although the
project was initially expected to cost $625 million, the final cost was much
higher. To this day, the WHIS continues to be the largest randomized controlled
trial of women’s health ever undertaken.
During the recruiting years of the WHIS, HRT kept gaining its popularity as a
preventive medicine. The number of HRT prescriptions kept rising throughout
the 1990s, reaching 90 million in 1999 (Hersh, Stefanick, and Stafford 2004).
More importantly, HRT gained acceptance for indications for which it was not
FDA-approved, most notably for prevention of heart disease. In a national
survey conducted by the National Heart, Lung, and Blood Institute, Rossouw
(1996) found that 66% of the surveyed cardiologists, internists, family doctors
and general practitioners prescribed HRT for prevention of coronary heart dis-
ease. Similarly, surveys of providers within several health maintenance organi-
zations from this period show that over 95% of providers believed that the
greatest benefit of HRT was in the prevention of cardiovascular conditions
(Rolnick et al. 1999) and that physicians who were convinced of the benefits
of HRT in preventing heart disease were more likely to prescribe it (Newton et al.
2001).
The HRT component of the WHIS was scheduled to run until 2005. However,
the clinical trial on combined estrogen–progestin hormones was abruptly termi-
nated on July 9, 2002, in the interest of safety, after an average follow up of 5.2
years.13 The results of the trial indicated that the combined estrogen-progestin
use would lead to 7 more heart attacks, 8 more strokes, 18 more blood clots and
8 more breast cancers annually per 10,000 post-menopausal women. They also
indicated that the combined HRT use would result in 5 less hip fractures and 6
less colon cancers per year per 10,000 post-menopausal women (Writing Group
for the Women 2002). Although the scientific results were officially published on
12 For more information on the WHIS, visit the study’s webpage by the National Heart, Lung,
and Blood Institute at http://www.nhlbi.nih.gov/whi/index.html and see the references and
links therein.
13 U.S. Department of Health and Human Services (2002).
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July 17, 2002, the study was released to the public early on July 9, 2002 because
of the importance of the findings.
The WHIS results made front pages in all major newspapers and were
covered in broadcasts on national television.14 In the wake of the WHIS news,
the stock prices of the producer of HRT medications used in the trial (Wyeth-
Ayerst Pharmaceuticals) fell by more than 24%.15 The news was followed by
statements from various policy makers and research groups. Most of these
statements focused on the results pertaining to the effects of long-term HRT
use on coronary heart disease. The FDA released a statement in August 2002
stating that “[t]he increased risks of breast cancer and thromboembolic disease
associated with estrogen and combination estrogen/progestin had previously
been known or suspected. The increased risk of cardiovascular disease, includ-
ing heart attack and stroke, in healthy women, is new information” (Food and
Drug Administration 2002, p. 1).16 The National Heart, Lung, and Blood Institute
announced September as the “menopause awareness month” and published a
booklet describing the WHIS findings (National Heart, Lung and Blood Institute
2005). Similarly, the North American Menopause Society concluded in its
October 2002 advisory panel that estrogen-progestin should not be used for
the prevention of heart disease (Watkins 2007).
The final verdict on the preventive role of long-term HRT came in January
2003 as FDA announced a formal name change for HRT drugs as “menopausal
hormone therapy” and mandated a boxed warning on the label of HRT drugs
about the increased risk of heart attacks, stroke and blood clots.17 Since then,
FDA recommends HRT use for relief of “moderate to severe vasomotor symptoms
associated with menopause, treatment of vulvar and vaginal atrophy and
14 Guthrie (2002), Kalota (2002), and Rubin (2002).
15 Peterson (2002).
16 The potential harmful effects of HRT on heart disease were first reported in August 1998 by
the Heart and Estrogen/Progestin Replacement Study (HERS). HERS was a randomized trial on
the effects of combined HRT medications on the prevention of a secondary heart attack or other
coronary event. The study consisted of 2,763 women between the ages of 44 to 67 who already
had heart disease. After 4 years of follow-up, it found that HRT was not effective in preventing a
secondary coronary event. Furthermore, it increased the risk of having a blood clot (Hulley et al.
1998). However, these results did not receive almost any media attention. Watkins (2007) notes
that none of the newspapers covered the story on their front page. For example, she writes that
the NY Times reported the HERS results only on page 20. Although the findings were reported
on some channels, there were no follow-ups. As we showed in Figure 1, the fact that HRT use
kept rising even after the HERS results is consistent with the observation that these results were
received with skepticism and did not impact the perceptions of patients or physicians pertaining
to the preventive effects of long-term HRT.
17 Food and Drug Administration (2003).
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prevention of postmenopausal osteoporosis.” FDA has also been emphasizing
that HRT products should be used at the lowest dose and for the shortest
necessary duration.
In summary, the WHIS was conducted at a time when HRT was widely used
and was perceived to be a miracle drug, effective as a short-term therapy in the
treatment of menopausal symptoms as well as a long-term therapy for the
prevention of serious diseases related to aging, most notably for the prevention
of cardiovascular disease. The abrupt termination of the combined HRT trial, the
highly publicized nature of the findings, the strong response of policy makers to
the news, and the size of the potentially affected group makes this an ideal
quasi-experiment when examining how medical information on drugs affects
preventive health behavior.
3 Data
To assess the effects of the WHIS findings on preventive health behavior of post-
menopausal women, we use data from the Behavioral Risk Factor Surveillance
System (BRFSS) for the period 1998–2007. The BRFSS is a nationally represen-
tative telephone survey designed to provide information on risky behavior and
preventive health practices of the civilian, noninstitutionalized adult population.
The survey is administered by individual states and the data are edited and
processed by the Centers for Disease Control and Prevention (CDC).
The BRFSS survey is made up of three parts. The core component includes a
set of questions that are asked by all states. However, these questions can be
asked in every year (the fixed-core questions) or in alternating years (the rotat-
ing-core questions). Every year, a set of questions pertaining to the latest health
issues are also added to the core component (the emerging-core questions).
These questions are evaluated in the following year to determine whether they
will be mainstreamed into the fixed or alternating cores in future surveys. In
addition to the core questionnaire, states can also administer questionnaires on
specific topics supported by the CDC (the optional modules component) or
develop and add their own questions (stated added questions component).
The BRFSS is an excellent dataset for the purposes of our research because it
is a very large annual survey including rich information on preventive health
habits of adults as well as basic demographic data. Other individual surveys that
cover similar information are either not as detailed as the BRFSS or suffer from
much smaller sample sizes. For example, the Current Population Survey has
detailed demographic data, as well as information on self-reported health status,
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but it has no information on health habits. The National Health Interview Survey
includes data on a range of health and health behavior but it has much smaller
sample sizes and the public-use data files do not contain state identifiers.
Controlling for state and state-year effects is particularly important in this
context because many states implemented welfare reforms during the 1990s
and this could have potentially impacted the health behavior of individuals
(Blank 2002; Bitler, Gelbach, and Hoynes 2005).
In the empirical analysis, we focus on a wide set of outcome variables con-
cerning preventive health care use. In particular, our outcomes include indicators
for having a checkup, mammography, professional breast exam, cholesterol check,
blood stool or flu shot in the past 12 months.18 In our regressions, we also control
for a set of observable characteristics of individuals. These include dummy
variables for age, race (non-Hispanic white, non-Hispanic black, non-Hispanic
other, Hispanic), marital status (married, single, never married), education (less
than high school, high school or GED, some college, college and more), annual
household income (less than $20,000, [$20,000–$25,000), [$25,000–$35,000),
[$35,000–$50,000), $50,000 and more) and current insurance status.19
Ideally we would like to include in our analysis sample post-menopausal
women. Unfortunately, BFRSS does not contain information on menopausal
status. For that reason, we restrict the sample to women in the post-menopausal
ages instead. The medical literature indicates that 75–80% of women reach
menopause by the age of 55 (Mckinlay 1996; Mckinlay, Brambilla, and Posner
2008). Since menopausal symptoms can last for a few years after its onset, we
include in our sample women aged 60 and above. The size of the analysis
sample changes depending on the outcome variable examined. All of our out-
comes are included in the core component of the BRFSS and thus are adminis-
tered by all states but none of them are part of the fixed-core questionnaire
during the whole sample period.20 This leaves us with a sample of 179,580–
367,836 observations, depending on the outcome studied.
18 We do not examine annual Pap Smear checks because there is a change in clinical guide-
lines in 2002 that impact women aged 60–69 and women aged 70 and above in different ways,
making it impossible to separate the impact of the guideline change from the impact of the
release of the WHIS findings.
19 Some of the control variables are missing for a number of observations (less than 1% for
ethnicity, education and marital status and around 26% for household income). We replace
these missing values with the sample average of the corresponding variable and we include as
additional controls indicators for missing values for each variable.
20 Questions on annual cholesterol check were administered as rotating-core questions and
asked in odd-numbered years. Questions on annual checkups were administered for the years
1998–2000 and 2005–2007. Questions on women’s health were part of the fixed-core between
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4 Empirical strategy
We are interested in examining the impact of drug safety information on preven-
tive health behavior. The WHIS provides an information shock on the safety of
long-term HRT use by post-menopausal women. As seen in Figure 1, before the
announcement of the WHIS findings, women aged 60–69 had much higher rates
of HRT use compared to women aged 75 or above.21 Therefore, we expect the WHIS
findings to have a larger impact on the preventive health behavior of women aged
60 to 69 relative to those aged 75 and above. Following this intuition, we set up a
difference-in-differences model where we compare changes in the preventive
health behavior of women aged 60–69 with changes in preventive health behavior
of women aged 75 and above.22 The key equation of interest can be described as:
Yit ¼ β0 þ β1Postt þ β2W6069i þ β3Postt W6069i þ "it ½1
where the unit of observation is individual i in year t. Yit is an outcome variable
capturing preventive health behavior, Postt is a dummy variable indicating the
period after the release of the WHIS results (2003 and after), and W6069i is a
dummy indicator representing women aged 60 to 69. This strategy is similar to
difference-in-differences models applied in other settings where one group is
treated more intensively than another group.23 The coefficient of interest, β3,
measures whether there is a differential change in preventive health behavior
between the pre- and post-periods in the more intensively treated group relative
to the less intensively treated group.
We enrich this basic specification in different ways. We add a set of control
variables describing the observable characteristics of each individual (Xit). We
replace the post-period dummy variable with a full set of survey month and year
indicators to allow for a more flexible time series pattern when controlling for
overall changes in the outcome. Finally, we include a set of state dummy
1998 and 2000 and were moved to rotating-core and administered in even-numbered years
between 2002 and 2006. Questions on blood stool test were part of the rotating core and were
asked in odd-numbered years between 1997 and 2001 and in even-numbered years between
2002 and 2006. Finally, questions on flu shot receipt were asked in 1999 and then in every year
between 2001 and 2007.
21 According to data from MEPS, during the period 1998–2002, HRT use among 60–69 year-old
women was 31% while it was only 12% for women aged 75 and above.
22 We thank an anonymous referee for this suggestion.
23 Recently Hoynes, Miller, and Simon (forthcoming) use such a strategy to examine the impact
of Earned Income Tax Credit (EITC) on infant health. In particular, they compare health changes
among children whose mothers have larger increases in EITC with those whose mothers have
lower increases in EITC.
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variables to correct for time-invariant or slowly changing state specific factors
that might impact the health or health behavior of residents.
Our key identifying assumption is that older post-menopausal women provide
the counterfactual of how younger post-menopausal women would have behaved
in the absence of the release of the WHIS findings. Although this is basically an
untestable assumption, we can test its plausibility by checking the evolution of
the outcomes in the pre-treatment period among the two groups. In particular, we
restrict our sample to 1998–2002 and estimate the following equation:
Yit ¼ α0 þ α1Xit þ α2W6069i þ
X2002
t¼1999
α3;tYeart þ
X2002
t¼1999
α4;tYeart W6069i þ cs þ νit
½2
Testing the joint significance of the coefficients of the interaction terms of year
and indicator for women aged 60–69 (Yeart W6069i) would provide informa-
tion on the equality of the pre-treatment trends in outcomes between women
aged 60–69 and women aged 75 and above.
Before presenting the results, two issues are worth discussing. The first issue
is why we do not employ a “traditional” differences-in-difference strategy where
post-menopausal women constitute the treatment group and a potentially
untreated group is used to construct the counterfactual of how post-menopausal
women would behave in the absence of the WHIS findings. In such a setting,
there are two potential natural comparison groups. The first candidate is the
group of middle-aged women who may use HRT on a short-term basis to
alleviate negative menopausal symptoms. While there were no changes in the
indications of short-term HRT use for the alleviation of menopausal symptoms,
Daysal and Orsini (2014) show that there were substantial spillover effects to the
HRT use of these women which led to economically significant reductions in
their short-term employment due to the resurgence of menopausal symptoms.
Given that employment is an important source of insurance coverage, it is then
possible that these women changed their preventive behavior, making them
unsuitable as a comparison group. The second natural comparison group is
men because hormone replacement is a therapy exclusive to women. The
major weakness of this comparison group is the known differences in preventive
habits among men and women, especially during older ages. Furthermore, one
cannot examine changes in preventive behavior pertaining to women’s health
when relying on men as a comparison group.
A second point worth noting is the reason why we do not examine the
impact of HRT use on preventive health behavior and instrument for HRT use
with the WHIS findings. The key identification assumption required in this case
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is the instrument excludability: that the WHIS findings impact health behavior
only through changes in HRT use. However, it is possible that the WHIS findings
impacted preventive health behavior by simply reminding women of various
health risks associated with post-menopause, thereby violating the exclusion
restriction. With these explanations in mind, we turn to our results.
5 Results
5.1 Descriptive statistics
Tables 1 and 2 provide the means and standard deviations of our outcome
and control variables from BRFSS. In Table 1, we present summary statistics
Table 1: Summary statistics for outcome variables: BRFSS Data, 1998–2007
Full sample Women: 60–69 Women: 75þ
Mean SD Mean SD Mean SD
All Years: 1998–2007
Checkup 0.848 0.359 0.826 0.379 0.877 0.328
Cholesterol check 0.793 0.405 0.780 0.414 0.808 0.394
Mammography 0.633 0.482 0.682 0.466 0.569 0.495
Professional breast exam 0.622 0.485 0.678 0.467 0.549 0.498
Blood stool 0.223 0.416 0.226 0.418 0.219 0.413
Flu shot 0.609 0.488 0.528 0.499 0.707 0.455
Pre-period: 1998–2002
Checkup 0.859 0.348 0.842 0.365 0.882 0.322
Cholesterol check 0.766 0.423 0.763 0.425 0.770 0.421
Mammography 0.634 0.482 0.685 0.465 0.561 0.496
Professional breast exam 0.629 0.483 0.681 0.466 0.556 0.497
Blood stool 0.245 0.430 0.251 0.433 0.237 0.426
Flu shot 0.598 0.490 0.527 0.499 0.694 0.461
Post-Period: 2003–2007
Checkup 0.839 0.367 0.810 0.392 0.873 0.333
Cholesterol check 0.808 0.394 0.792 0.406 0.828 0.377
Mammography 0.633 0.482 0.677 0.468 0.582 0.493
Professional breast exam 0.610 0.488 0.673 0.469 0.537 0.499
Blood stool 0.192 0.394 0.189 0.391 0.196 0.397
Flu shot 0.615 0.487 0.529 0.499 0.713 0.452
Notes: Each block represents the weighted mean and standard deviation of the outcome
variable in a separate group based on indicators of treatment intensity and treatment period.
Weighting is based on finalwt variable from the BRFSS.
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for the full sample and separately for more and less intensively treated
groups, as well as for sub-periods determined according to the release of
the WHIS findings. These figures provide some preliminary, descriptive evi-
dence on the effects of the drug safety information provided by the WHIS
findings on preventive health behavior. The table suggests that women aged
60–69 did not adopt more preventive checks during the post-period as com-
pared to women aged 75 or above. For example, among women aged 60–69,
the fraction who reported having a mammogram within the last year declined
by 1.2% between the pre- and post-announcement periods of the WHIS,
whereas women aged 75 and above experienced an increase of almost 4%.
Similarly, annual checkups among the more intensively treated group
declined by almost 4% from 84.2% in pre-period to 81% in the post-period,
whereas the corresponding change for women in the comparison group was
around 1%. In the next section, we provide our estimation results and check if
Table 2: Summary statistics for control variables: BRFSS Data, 1998–2007
Full sample Women: 60–69 Women: 75þ
Mean SD Mean SD Mean SD
Age 71.498 8.803 64.333 2.869 80.394 4.541
Non-Hispanic White 0.813 0.390 0.788 0.409 0.845 0.362
Non-Hispanic Black 0.082 0.274 0.093 0.291 0.067 0.251
Non-Hispanic Other 0.036 0.185 0.041 0.198 0.029 0.168
Hispanic 0.060 0.238 0.072 0.258 0.046 0.210
Less than high school 0.185 0.388 0.153 0.360 0.224 0.417
High school 0.376 0.484 0.376 0.484 0.375 0.484
Some college 0.240 0.427 0.247 0.432 0.231 0.421
College and more 0.194 0.396 0.220 0.414 0.163 0.369
Married 0.486 0.500 0.614 0.487 0.328 0.469
Single 0.478 0.500 0.349 0.477 0.638 0.481
Never married 0.033 0.179 0.034 0.182 0.032 0.175
Less than $20,000 0.258 0.437 0.215 0.411 0.311 0.463
[$20,000, $25,000) 0.105 0.306 0.099 0.299 0.112 0.316
[$25,000, $35,000) 0.126 0.332 0.134 0.341 0.117 0.322
[$35,000, $50,000) 0.110 0.312 0.137 0.344 0.076 0.265
$50,000 and More 0.142 0.349 0.201 0.401 0.068 0.252
Insured 0.947 0.223 0.923 0.266 0.977 0.149
Notes: Each cell represents the weighted mean and standard deviation of the variable in a
separate group based on indicators of treatment intensity. Weighting is based on finalwt
variable from the BRFSS.
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the observed differences documented here persist after controlling for other
potentially confounding factors.
5.2 Baseline results
Table 3 presents the main results. Each row provides results on a separate outcome
variable. The first column provides means of the outcome variables among women
Table 3: Effects of the WHIS results on preventive health behavior
Pre-period mean of the
outcome among women
Simple DID DID
(1) (2) (3)
Checkup 0.842 –0.022 –0.018
(N ¼ 263,543) (0.004) (0.004)
[0.295]
Cholesterol check 0.763 –0.030 –0.027
(N ¼ 218,218) (0.010) (0.009)
[0.486]
Mammography 0.685 –0.029 –0.033
(N ¼ 197,717) (0.009) (0.007)
[0.132]
Professional breast exam 0.681 0.011 0.002
(N ¼ 194,726) (0.009) (0.008)
[0.511]
Blood stool 0.251 –0.020 –0.021
(N ¼ 179,580) (0.006) (0.005)
[0.695]
Flu shot 0.527 –0.017 –0.010
(N ¼ 367,836) (0.007) (0.007)
[0.699]
Notes: Each row provides results on a separate outcome variable. The first column provides
means of the outcome variables among women aged 60–69 during the pre-WHIS period.
Columns (2)–(3) provide the effects of the drug safety information provided by the WHIS on
preventive health behavior. Covariates in column (3) include complete set of dummies for age,
race, marital status, income, insurance status, month and year of survey and state of residence.
Regressions are weighted by the final weights (finalwt) provided in the BRFSS. Robust standard
errors clustered at the state level are shown in parenthesis below coefficients. Column (3) also
provides in square brackets the p-value corresponding to a test of the equality of the pre-
treatment trends in outcomes between women aged 60–69 and women aged at least 75.
*p < 0:10, **p < 0:05, ***p < 0:01.
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aged 60–69 during the pre-WHIS period. Columns (2)–(3) provide the effects of the
drug safety information provided by the WHIS on preventive health behavior. In
order to gauge the importance of time-varying characteristics, we first estimate in
column (2) a simple difference-in-differences model described by eq. [1], and then
in column (3) models from our full specification. Regressions are weighted by the
final weights provided in the BRFSS. Robust standard errors clustered at the state
level are shown in parenthesis below coefficients.
The results consistently show that women aged 60–69 reduced their pre-
ventive health care use relative to women aged 75 and above during the post-
WHIS period. The estimates are statistically significant for all outcomes except
annual flu shots and professional breast exams. For example, the estimate on
mammography checks in column (3) suggests that women aged 60–69 were 3.3
percentage points less likely to have an annual mammogram during the post-
WHIS period as compared to women aged 75þ , a 4.8% reduction when com-
pared to the mean of the outcome among women aged 60–69 during the pre-
treatment period. Similarly, the results on annual checkup, cholesterol check
and blood stool test indicate that individuals in the more intensively treated
group were respectively 1.8, 2.7 and 2.1 percentage points less likely to have
these preventive checks during the post-WHIS period as compared to the indi-
viduals in the less intensively treated group. There results correspond to 2.14%,
3.54% and 8.37% decline at the pre-period mean of the outcome among women
aged 60–69.
As we described before, the key identifying assumption in difference-in-
differences models is that women aged 75 and above provide the counterfactual
of what would have happened to women aged 60–69 in the absence of the WHIS
intervention. Although, this is basically an untestable assumption, we can shed
some light on it by checking the evolution of the outcomes in the pre-treatment
period among the two groups. In order to do so, we run eq. [2] described in
Section 4. The p-values corresponding to the null hypothesis testing the sig-
nificance of the interaction variables (i.e. equality of the pre-treatment trends in
outcomes among women aged 60–69 and 75þ ) are provided in column (3) in
square brackets. It is reassuring that for all of our selected outcomes, we fail to
reject the equality of the pre-treatment trends in outcomes among women 60–69
and women aged 75þ with substantially high p-values.
5.3 Robustness checks
In this section, we provide additional analyses checking the robustness of the
baseline estimates. Table 4 presents the results. Each column represents results
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Table 4: Robustness checks
Checkup Cholesterol check Mammography Breast exam Blood stool Flu shot
(1) (2) (3) (4) (5) (6)
A: Baseline
Postt W6069i –0.018 –0.027 –0.033 0.002 –0.021 –0.010
(0.004) (0.009) (0.007) (0.008) (0.005) (0.007)
N 263,543 218,218 197,717 194,726 179,580 367,836
B: Logit
Postt W6069i –0.013 –0.029 –0.033 0 –0.021 –0.013
(0.004) (0.009) (0.007) (0.008) (0.006) (0.006)
N 263,543 218,218 197,717 194,726 179,580 367,836
C: State-specific time trend
Postt W6069i –0.017 –0.026 –0.033 0.002 –0.022 –0.009
(0.004) (0.009) (0.007) (0.009) (0.005) (0.007)
N 263,543 218,218 197,717 194,726 179,580 367,836
D: Control: Women aged 70þ
Postt W6069i –0.013 –0.020 –0.028 0.000 –0.014 –0.003
(0.004) (0.007) (0.007) (0.007) (0.006) (0.007)
p-Value 0.201 0.493 0.249 0.645 0.081 0.086
N 324,883 269,565 245,517 241,799 222,355 453,490
E: Control: Women aged 80þ
Postt W6069i –0.019 –0.034 –0.043 0.011 –0.027 –0.020
(0.006) (0.014) (0.008) (0.010) (0.007) (0.008)
p-Value 0.057 0.377 0.571 0.502 0.409 0.110
N 209,898 173,790 156,116 153,897 142,083 292,557
F: Control: Men
Postt W6069i –0.014 –0.012 –0.024 0.001
(0.006) (0.007) (0.010) (0.007)
p-Value 0.851 0.844 0.011 0.066
N 240,341 202,734 165,025 334,865
G: Cluster: State-Year
Postt W6069i –0.018 –0.027 –0.033 0.002 –0.021 –0.010
(0.006) (0.008) (0.009) (0.010) (0.008) (0.009)
N 263,543 218,218 197,717 194,726 179,580 367,836
H: Heterogeneous effects by education
High school and less
Postt W6069i –0.015 –0.022 –0.029 0.009 –0.022 –0.012
(0.007) (0.012) (0.014) (0.012) (0.010) (0.007)
Mean of outcome [83.7] [74.5] [64.3] [63.6] [22.1] [50.5]
p-Value 0.190 0.000 0.280 0.550 0.466 0.651
N 142,713 117,294 110,775 108,976 99,295 199,251
Some college and more
Postt W6069i –0.020 –0.028 –0.039 –0.009 –0.018 –0.005
(0.006) (0.011) (0.010) (0.012) (0.009) (0.008)
Mean of outcome [84.9] [78.6] [74.3] [74.2] [28.8] [55.6]
p-Value 0.586 0.901 0.634 0.223 0.002 0.359
N 119,811 100,147 86,299 85,136 79,744 167,244
(continued )
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using a different outcome variable. Panel A reproduces our baseline estimates
from the specification including all controls for reference (compare to column (3)
in Table 3). Panels B and C check the robustness of the results to functional form
and model specification. In Panel B, we examine the appropriateness of using a
linear model by estimating logit regressions. The average marginal effects con-
firm the previous baseline estimates produced by the linear specification. For the
remainder of the checks, we therefore report results from linear models for the
sake of brevity.
Panel C attempts to account for a potential bias arising from changes in
state-based preventive health policies. The 1990s and 2000s witnessed an
increased awareness in the importance of access to preventive health services.
The U.S. Department of Health and Human Services released on September 6,
1990 a report detailing national public health goals and objectives for the
decade. The report (Healthy People 2000: National Health Promotion and
Disease Prevention Objectives) was followed by another initiative (Healthy
People 2010: Objectives for Improving Health), released on January 25, 2000,
updating the goals for the year 2010. Both of these reports placed great emphasis
on the role of preventive services. For example, of the 22 focus areas in
the earlier report, 21 were related to health promotion, health protection and
preventive services. The development and implementation of these goals
Table 4: (Continued )
Checkup Cholesterol check Mammography Breast exam Blood stool Flu shot
(1) (2) (3) (4) (5) (6)
I: Placebo regressions
Post-period is 1999 and 2000
Postt W6069i –0.010 –0.010 0.007
(0.009) (0.013) (0.020)
N 59,578 59,134 58,369
Post-period is 2000
Postt W6069i 0.010 –0.008 0.018
(0.008) (0.012) (0.015)
N 59,578 59,134 58,369
Post-period is 2001
Postt W6069i –0.004 0.012 0.023
(0.013) (0.014) (0.020)
N 42,913 43,216 44,650
Notes: Each column provides results on a separate outcome variable. For a description of
checks, see the text in Section 5.3. Regressions are weighted by the final weights (finalwt)
provided in the BRFSS. Robust standard errors clustered at the state level are shown in
parenthesis below coefficients. *p < 0:10, **p < 0:05, ***p < 0:01.
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represented a concerted effort at the national, state and community level. To the
extent that the implementation of the programs associated with these initiatives
varied across states, this could contaminate our estimates. To examine this
issue, we add state-specific year effects to our baseline estimates. This should
capture any effect that is common to all individuals within a unique state-year
cell. The results provided in the third row are virtually the same as those in the
baseline model.
The following three Panels investigate the sensitivity of our findings to the
chosen comparison group.24 Panel D expands the comparison group to women
aged 70 and above while Panel E restricts it to women aged at least 80 years old.
In both cases, we confirm our main finding: women aged 60–69 group were
significantly less likely to use preventive care after the announcement of the
WHIS results, as compared to the group of older women. Furthermore, the
magnitudes of the estimates are consistent with our prior that these behavioral
changes are driven by changes in HRT use – as the intensity of treatment in the
comparison group (i.e. the share of women with HRT use) declines, the size of
our estimates increases. In Panel F, we focus on individuals aged 60–69 and use
men as the comparison group. We again find that women aged 60–69 were less
likely to use preventive care after the WHIS relative to men of similar ages. The
robustness of our results to different comparison groups lends support to the
claim that our results are not driven by other policy interventions that happen
around the time of the release of the WHIS findings and differentially impact the
treatment and comparison groups.
In Panel G, we examine whether the level at which we cluster the standard
errors changes our results qualitatively. Since the BRFSS sample individuals at
the state-year level (and this may cause correlations among the error terms at
this level), we re-estimate the baseline model and cluster the standard errors at
the state-year level.25 As the table shows, clustering at a finer level does not
impact our initial conclusions.
In Panel H, we examine the heterogeneity in the response to the WHIS
results by educational attainment. Economic theory suggests that education
may have an important impact on preventive health care use. For example,
Grossman (1972) and Schultz (1975) argue that education may improve an
individual’s health production function and increase allocative efficiency
through enhanced learning and ability to process information. Figure 2 shows
24 The p-values corresponding to a test of equality of the pre-treatment trends in outcomes
among treatment and comparison groups are provided under the coefficient estimates.
25 This can also be interpreted as a test of the sensitivity of the results to differences between
effective and nominal sample size.
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the percentage of women in MEPS who reported using HRT separately by
treatment intensity and by educational attainment.26 The graph shows that
HRT use is much higher among those 60 to 69 than those 75 and older,
regardless of the level of education. In addition, consistent with economic
theory, it shows that HRT use is higher among women with at least some college
education (relative to those with at most a high school degree), regardless of
treatment intensity. However, all four groups show comparable relative reduc-
tions in HRT use after the release of the WHIS results, perhaps because HRT use
is mainly decided by physicians. For example, among the lower-educated
women in the more (less) intensively treated group, HRT use declined from 29
(11) percentage points during the pre-period (1998–2002) to 12 (5) percentage
points during the post-period (2003–207). Similarly, among the higher-educated
women in the more (less) intensively treated group, HRT use declined from 35
(16) percentage points during the pre-period to 16 (7) percentage points during
the post-period. Our results in Panel H of Table 4 show that, following the
announcement of the WHIS findings, more intensively treated women at both
Figure 2: Prevalence of HRT among post-menopausal women by Education: Medical Expenditure
Panel Survey, 1998–2007
26 Unfortunately, the NAMCS does not include information on the educational attainment of
the patient observed in the office-visit.
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levels of educational attainment had lower preventive care use when compared
to women in the less intensively treated group. While the estimates among the
higher educated are in general larger in absolute value, they are similar in
relative terms and we cannot reject the equality of the estimates across different
education groups.27
In Panel I, we conduct placebo tests in the spirit of Bertrand, Dufflo, and
Mullainathan (2004). In particular, we restrict the data to pre-WHIS period and
assign “fake” intervention years. We then estimate our baseline model using
these data and the fake intervention indicator. Since different outcome variables
are included in BRFSS in different years, the span of the pre-period (and hence
the fake intervention year) changes by outcome. The results show that these fake
intervention years do not have any differential impact on preventive health care
use of women in the more intensively treated group relative to those in the less
intensively treated group.
Finally, given the large number of outcomes we examine, we combine our
various measures of preventive health care use into a single index in order to
reduce the dimensionality of our analysis. This approach has the added advan-
tage of avoiding problems of multiple testing, i.e. the fact that with many
outcomes, the main independent variable will be statistically significant in at
least some cases. Following Kling, Liebman, and Katz (2007), we create our
index measure as the average of standardized individual measures. Using this
index measure as the outcome in our baseline specification yields a highly
significant coefficient of –0.175 (s.e. 0.007, N ¼ 410,605), confirming that our
baseline findings are not driven by multiple testing issues.
5.4 Potential mechanisms
Our results are consistent with four theories. According to the expected utility
theory, a rational risk averse individual would be willing to sacrifice current
consumption in order to have improved health in the future. Individuals may
rationally deviate from the optimal choices if they display cognitive dissonance
(Akerlof and Dickens 1982). Cognitive dissonance, in the most basic sense,
means that individuals are uncomfortable holding contradicting beliefs.
According to psychologists, most situations that lead to cognitive dissonance
challenge individuals’ perception of themselves as “smart and nice” people.
27 Pre-period means of the outcome variables among women aged 60–69 are reported under
the coefficient estimates along with the p-values corresponding to a test of equality of the pre-
treatment trends in outcomes among more and less intensively treated groups.
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Whenever the individual is faced with a situation where there is a discrepancy
between beliefs and behaviors, (s)he must either change the behavior or the
belief in order to reduce the psychological discomfort. The abrupt termination of
the WHIS and its findings on the preventive power of long-term HRT products
may have created conflicting feelings among some individuals. In response to
this news, they may have changed their perception regarding the trustworthi-
ness of the medical sciences and thus may have decided to ignore all general
recommendations on the use of preventive health care.
Our results are also consistent with behavioral models where time prefer-
ence plays an important role. The theory of hyperbolic discounting suggests that
present-biased preferences could explain the lack of motivation for healthy
lifestyle habits that have immediate costs but delayed and uncertain benefits
(Laibson 1997; Loewenstein, Brennan, and Volpp 2007). WHIS findings may
have induced some individuals to engage in present-biased behavior by redu-
cing their expected lifespan and thus changing their time preferences.
Fatalism is another possible explanation for our findings. Fatalism consists
in the belief that no matter what a person does, his/her actions can do too little
to impact future outcomes (Wu, 2005). A picturesque example is one of the
athlete who “throws in the towel” when (s)he thinks that the possibility of
winning a competition is low. If post-menopausal women believed that HRT
drugs consisted of an important source of preventive care that enabled them to
further adopt healthy life choices, it is entirely possible that the WHIS findings
led some of these women to conclude that healthy lifestyles alone would not be
adequate to protect them and thus “throw in the towel” and give up preventive
care. Fatalistic tendencies are not at all uncommon in determining preventive
health behavior. For example, Kremer (1996) shows that an increase in the
probability of contracting HIV might lead individuals with a high number of
sexual partners to increase sexual activity because they become fatalistic about
the probability of contracting the disease.
Finally, our results are consistent with the predictions of the health belief
model – one of the most accepted theories in the field of health education.28 The
original formulation of this theory is much like a cost–benefit calculation. An
individual is predicted to adopt preventive behavior the higher the probability of
getting a disease that is sufficiently serious in severity (i.e. “perceived threats”),
the higher the effectiveness of the said action in reducing the threat (i.e.
“perceived benefits”) and the lower the costs of taking that action (i.e. “per-
ceived barriers”). The later formulations of the theory include two additional
concepts: “cues to action” that describes situations, such as provision of
28 For more details, see Glanz, Rimer, and Viswanath (2008).
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educational materials and counseling, that can increase an individual’s readi-
ness to act and “self-efficacy” that refers to one’s confidence in his/her ability to
take actions to produce the required outcomes. Self-efficacy is, thus, related to
our argument on fatalism. Some post-menopausal women could perceive med-
ical products and preventive behavior as complementary goods so the loss of
perceived protection by HRT could lead to a reduction in women’s confidence to
prevent serious diseases associated with aging by solely relying on a healthy life
style and using preventive care.
6 Conclusion
In this paper, we examine the response to the medical findings from the WHIS
and the subsequent public policy actions that documented the harmful health
effects of long-term HRT. We first show that following the release of the WHIS
findings, HRT use and prescriptions declined substantially among women aged
60 and above. We then implement difference-in-differences models to examine
the impact of these new medical information on preventive health care use. In
particular, we compare the change in outcomes between the pre- and post-
announcement periods of the WHIS results among 60 to 69 year-old women
(who have higher rates of HRT use) with the change among women aged 75 and
above (who have much lower rates of HRT use). Our results point to statistically
and economically significant reductions in post-menopausal women’s likelihood
of having an annual checkup, cholesterol check, mammography and blood
stool test.
As the costs of producing and disseminating new medical information rise,
understanding how consumers may respond to this information becomes even
more important. Taken together, our results suggest that policies aimed at
raising awareness on the safety of medications may have unintended spillover
effects on preventive health behavior that reduce the net value of the new
medical information.
Appendix
Since the BRFSS does not contain information on the use of prescription med-
ication, we employ additional data from the Medical Expenditure Panel Survey
(MEPS) and the National Ambulatory Medical Care Survey (NAMCS) to document
changes in HRT use. The household component of MEPS includes data from a
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nationally representative sample of the U.S. civilian non-institutionalized popu-
lation. Respondents are interviewed about their medical expenditures and utili-
zation of medical services over a period of 2 years through five interview rounds.
Part of the household component (the prescribed medicine file) provides infor-
mation on the prescription medicines purchased by the respondent in each
round along with the three-digit ICD-9 codes denoting the medical conditions
for which the prescription medicine was purchased. We supplement the MEPS
household component data with additional information from the Physician’s
Desk Reference Companion Guide (PDRCG), an annual publication on prescrip-
tion drugs available on the market. The Physician’s Desk Reference Companion
is regarded as one of the most respected and used handbooks by physicians to
select medications for their patients (Watkins 2007). We use the “Therapeutic
Indications Index,” a list of medications and the conditions for which they are
indicated, to identify the HRT drugs that were available during our analysis
period. Trade-name drugs that contain hormones to treat menopause and their
generic substitutes are listed under the label “Menopause, Vasomotor Symptoms
of.” We classify an individual as using HRT if the person reports purchasing at
least one HRT product at any time during the round.
NAMCS is a national survey on the use of ambulatory medical care services
in the United States. The unit of observation in the data is a physician–patient
visit based on a random sample of visits to non-federally employed physicians.29
It provides information on the patient’s demographic characteristics and symp-
toms, the physician’s diagnoses, the prescribed medications associated with the
visit as well as the therapeutic class of the medications. The therapeutic class of
drugs is based on the National Drug Code Directory for the period 1998–2005
and its successor the Lexicon Plus, a proprietary database of Cerner Multum,
Inc. for the period 2006–2007. The public data files provide information on up to
six medications for 1998–2003 and eight medications for 2004–2007. They also
provide one therapeutic class for each medication for 1998–2001, three thera-
peutic classes for 2001–2005 and four therapeutic classes for 2006–2007. In
cases when there are multiple therapeutic class codes, we use the primary
code associated with the medication. We classify a visit as resulting with an
HRT prescription if any of the listed medications has a (primary) National Drug
29 The data excludes visits to physicians in the specialties of anesthesiology, pathology and
radiology. It also excludes telephone consults, visits that occur outside the physician’s office,
including the hospital (provided that the physician does not have a private office there) and
other institutions that are primarily responsible for the patients’s care (e.g. nursing homes) and
visits with only administrative purposes (e.g. filling forms).
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Code of “1034 Estrogens/Progestins” or Multum code of “183 Estrogens” or “185
Progestins”.
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